Last $105.61 USD
Change Today -0.11 / -0.10%
Volume 245.5K
LH On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 3:10 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

laboratory crp of amer hldgs (LH) Snapshot

Open
$105.70
Previous Close
$105.72
Day High
$106.49
Day Low
$105.28
52 Week High
11/15/13 - $108.00
52 Week Low
12/11/13 - $87.01
Market Cap
9.0B
Average Volume 10 Days
798.7K
EPS TTM
$6.17
Shares Outstanding
84.8M
EX-Date
--
P/E TM
17.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for LABORATORY CRP OF AMER HLDGS (LH)

laboratory crp of amer hldgs (LH) Related Businessweek News

No Related Businessweek News Found

laboratory crp of amer hldgs (LH) Details

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company provides testing services that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases. It also offers specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, women's health, cardiovascular disease, identity, forensics, infectious disease, endocrine sciences, oncology, occupational testing, and pain management. The company provides its services through a sales force to the physicians, hospitals, managed care organizations, governmental agencies, employers, pharmaceutical companies, and other independent clinical laboratories. It operates a national network of 44 primary laboratories and approximately 1,700 patient service centers, as well as branches and STAT laboratories. Laboratory Corporation of America Holdings has collaboration with university, hospital and academic institutions, such as Duke University, The Johns Hopkins University, the University of Minnesota, and Yale University to license and commercialize new diagnostic tests. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

34,000 Employees
Last Reported Date: 02/25/14
Founded in 1971

laboratory crp of amer hldgs (LH) Top Compensated Officers

Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $587.2K
Chief Legal Officer, Chief Compliance Officer...
Total Annual Compensation: $371.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $345.3K
Compensation as of Fiscal Year 2013.

laboratory crp of amer hldgs (LH) Key Developments

Laboratory Corporation of America Holdings Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Full Year 2014

Laboratory Corporation of America Holdings announced consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $1,516.4 million, an increase of 3.3% over last year's $1,468.2 million. The increase in sales was the result of test volume, measured by requisitions, and fold-in acquisitions, which was partially offset by mix. Operating income for the quarter was $246.7 million, compared to $269.3 million in the second quarter of 2013. The company recorded restructuring and special items of $6.7 million during the second quarter of 2014, compared to $6.6 million in the second quarter of 2013. Adjusted operating income (excluding restructuring and special items) for the quarter was $253.4 million, or 16.7% of sales, compared to $275.9 million in the second quarter of 2013, or 18.8% of sales. The decline in operating income was due to mix, cost inflation and an increase in bad debt expense, which was partially offset by increased volume and improved productivity. Earnings before income taxes were $232.5 million against $250.0 million a year ago. Net earnings attributable to the company were $141.3 million and earnings per diluted share (EPS) were $1.64, compared to $151.9 million and $1.62, respectively, in the second quarter of 2013. EPS benefitted from a $0.06 per share gain on the sale of an investment as well as the company's share repurchase program. Adjusted EPS (excluding amortization, restructuring and special items) was $1.84 in the second quarter, compared to $1.80 in the second quarter of 2013. Net cash provided by operating activities for the quarter was $207.4 million, compared to $137.6 million in the second quarter of 2013, as the company benefitted from improved working capital. Capital expenditures totaled $48.1 million, compared to $48.8 million in the second quarter of 2013. Free cash flow (operating cash flow less capital expenditures) was $159.3 million, compared to $88.8 million in the second quarter of 2013. For the year-to-date, the company reported net sales of $2,947.1 million, an increase of 1.3% year over year last year's $2,909.1 million. The increase in sales was the result of fold-in acquisitions and test volume measured by requisitions, which was partially offset by mix. Operating income was $450.0 million, compared to $531.3 in 2013. The company recorded restructuring and special items of $14.3 million during the first half of 2014, compared to $14.1 million in the first half of 2013. Adjusted operating income was $464.3 million, or 15.8% of sales, compared to $545.4 in the first half of 2013, or 18.8% of sales. The decline in operating income was due to mix, cost inflation and an increase in bad debt expense, which was partially offset by increased volume and improved productivity. Earnings before income taxes were $420.2 million against $491.4 million a year ago. Net earnings attributable to the company were $254.4 million and EPS were $2.94 in the first half of 2014, compared to $299.2 million and $3.18, respectively, in the first half of 2013. EPS benefitted from a $0.11 per share gain on the sale of an investment as well as the company's share repurchase program. Adjusted EPS was $3.35, compared to $3.53 in the first half 2013. Net cash provided by operating activities for the first half of 2014 was $349.7 million, compared to $335.8 million in the first half of 2013, as the company benefitted from improved working capital. Capital expenditures totaled $104.6 million in the first half of 2014, compared to $90.5 million in the first half of 2013. Free cash flow was $245.1 million in the first half of 2014, compared to $245.3 million in the first half of 2013. The company provided earnings guidance for the full year 2014. For the year, the company expects revenue growth in 2014 of approximately 2.0% over 2013. Adjusted EPS expected to be in the range of $6.50 to $6.75 compared with prior guidance of $6.40 to $6.70, which excludes the impact of any share repurchase activity after June 30, 2014. Operating cash flow expected to be in the range of $780 million to $820 million. Capital expenditures expected to be in the range of $185 million to $205 million and free cash flow of $575 million to $635 million.

Laboratory Corp. of America Holdings to Report Q2, 2014 Results on Jul 18, 2014

Laboratory Corp. of America Holdings announced that they will report Q2, 2014 results Pre-Market on Jul 18, 2014

Laboratory Corp. of America Holdings, Q2 2014 Earnings Call, Jul 18, 2014

Laboratory Corp. of America Holdings, Q2 2014 Earnings Call, Jul 18, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LH:US $105.61 USD -0.11

LH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $31.04 USD -0.12
Fluidigm Corp $28.29 USD +1.16
Genomic Health Inc $26.30 USD +0.315
QIAGEN NV €18.64 EUR +0.01
Quest Diagnostics Inc $62.30 USD +0.19
View Industry Companies
 

Industry Analysis

LH

Industry Average

Valuation LH Industry Range
Price/Earnings 17.6x
Price/Sales 1.5x
Price/Book 3.4x
Price/Cash Flow 14.6x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORY CRP OF AMER HLDGS, please visit www.labcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.